Drug intelligence / Profile preview

PK081

Development stage: Unknown
Lead developer: PharmaKure
Modality: Small Molecules
Administration: Oral

Overview

PK081 is a repurposed small molecule drug candidate being developed by PharmaKure for the treatment of Parkinson's disease. The drug was identified using PharmaKure's proprietary ALZ-MET platform, which screens for existing drugs that can be repositioned to treat neurodegenerative diseases by targeting toxic protein aggregates. PK081 specifically targets alpha-synuclein, aiming to inhibit its aggregation into the pathological fibrils and Lewy bodies that characterize Parkinson's disease. By preventing the formation of these toxic species, PK081 is intended to act as a disease-modifying therapy. The candidate is currently in early clinical development, with pipeline data indicating it has reached Phase 1 trials.

Targets

aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on PK081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PK081.

Explore the full profile